These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30829871)

  • 21. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed response after repeated
    Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
    Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
    Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.
    Aryana K; Zarehparvar Moghadam S; Salek R; Divband G
    Clin Nucl Med; 2018 Apr; 43(4):273-275. PubMed ID: 29401146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A
    Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
    Ferdinandus J; Eppard E; Gaertner FC; Kürpig S; Fimmers R; Yordanova A; Hauser S; Feldmann G; Essler M; Ahmadzadehfar H
    J Nucl Med; 2017 Feb; 58(2):312-319. PubMed ID: 27587707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 32. Reply to Rahbar K et al.
    Yadav MP; Ballal S; Tripathi M; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):168-169. PubMed ID: 27695908
    [No Abstract]   [Full Text] [Related]  

  • 33. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
    Zhang J; Kulkarni HR; Singh A; Baum RP
    Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
    Fendler WP; Kratochwil C; Ahmadzadehfar H; Rahbar K; Baum RP; Schmidt M; Pfestroff A; Lützen U; Prasad V; Heinzel A; Heuschkel M; Ruf J; Bartenstein P; Krause BJ
    Nuklearmedizin; 2016 Jun; 55(3):123-8. PubMed ID: 27350005
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
    Wei X; Schlenkhoff C; Schwarz B; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2017 Sep; 42(9):704-706. PubMed ID: 28719450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
    Gupta M; Karthikeyan G; Choudhury PS; Babu Koyyala VP; Sharma M; Jain P; Talwar V; Singh A; Rawal S
    Cancer Invest; 2020 Sep; 38(8-9):486-492. PubMed ID: 32804008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
    J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Dry Eye Toxicity After Treatment With
    Pepin A; Lee V; O'Brien S; Mulugeta P; Taunk NK
    Pract Radiat Oncol; 2024; 14(4):301-304. PubMed ID: 38631608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
    Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
    Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.